pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)
Amgen
Amgen clinical programs — 17 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- One Amgen Center Drive, Thousand Oaks, CA 91320, US
- Founded
- 1980
- Employees
- 40,212
- Programs
- 96
- Drugs
- 124
- Patents
- 25
Amgen projects
17 ClinicalTrials.gov programs sponsored by Amgen.
Amgen has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
20160323
Amgen
Small Cell Lung Cancer
1 trial -
20180146
Amgen
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1 trial -
20190135
Amgen
Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation
1 trial -
20200469
Amgen
Extensive Stage Small cell lung cancer (ES-SCLC)
1 trial -
20220028
Amgen
Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.
1 trial -
20230151
Amgen
Asthma
1 trial -
20230167
Amgen
Thoracic tumors with homozygous MTAP-deletion
1 trial -
20230223
Amgen
Gastrointestinal tract, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (MTAP)-deletion
1 trial -
20230237
Amgen
Newly diagnosed localized Intermediate or High‐Risk Prostate Cancer
1 trial -
20230298
Amgen
Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
1 trial -
20240031
Amgen
KRAS Altered Advanced or Metastatic Solid Tumors
1 trial -
20240124
Amgen
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
20250004
Amgen
microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors
1 trial -
A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer
Amgen
Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer
1 trial -
Comparison between ABP 234 and Keytruda® (Pembrolizumab)
Amgen
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
1 trial -
Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer
Amgen
Small Cell Lung Cancer
1 trial -
Tarlatamab
Amgen
Neuroendocrine Prostate Cancer
1 trial
Frequently asked questions
How many clinical projects does Amgen have?
17 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.